Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Recognizing 'Intoxication'
One well-known and often deadly consequence of alcohol intoxication is impaired driving. Yet still today, it is difficult for even trained observers to fully identify "intoxication," given that so many factors contribute to it. This review examines the very definition of intoxication, as well as methods designed to prevent impaired driving.
buy viagra
What Is Gonorrhea? What Causes Gonorrhea?
Gonorrhea (from Late Latin gonorrhoia where gonos means "seed" and rhoe means "flow") is a sexually transmitted bacterial infection that tends to attack the mucous membranes of the body. It is the second most common sexually transmitted disease in the U.S.; the first being Chlamydia. The bacteria reside in the warm and moist body cavities of both men and women and are highly contagious. Gonorrhea is the most common cause of female infertility and is also known as "the clap" or "the drip". Only a fraction of women infected with the disease show any symptoms, leaving them unaware of their condition. If left untreated, gonorrhea patients can develop pelvic inflammatory disease or PID (women), or an inflammation of the epididymis, prostate gland, or urethral structure (men), all of which are far more difficult to treat.
News of the day
Angina: Risk Of Heart Attack And Death Doubles In Men
A study just published on bmj.com reports that the risk of heart attack is multiplied by two for men who have angina. Also their risk of suffering a heart disease-related death is three times higher than for women with the same condition.
Nutrition

FDA Accepts Final Section Of NDA Filing For LUCASSIN(R)

Orphan Therapeutics, LLC and Ikaria Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing seeking marketing approval for LUCASSIN(R) (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type 1. The filing was completed on May 4, 2009, and LUCASSIN has been granted Priority Review as well as Orphan Drug status and Fast Track designation. HRS Type 1 is the development of kidney failure in patients with late-stage liver cirrhosis in the absence of any other cause. It is characterized by rapid onset of renal failure with a high mortality rate that exceeds 80% within three months. In September 2008, Ikaria acquired the North American rights to LUCASSIN, including responsibility for manufacturing, distribution, marketing, sales, customer service and post-market development. Those rights will be transferred to Ikaria following marketing approval. LUCASSIN is a synthetic vasopressin analogue that acts via the vasopressin V1 receptor as a systemic vasoconstrictor, mainly in the splanchnic (abdominal) circulation, which appears to increase effective arterial volume and improves renal blood flow, thereby improving renal function in patients with HRS. Terlipressin was recently approved in France, Ireland, Spain and South Korea for the treatment of patients with HRS Type 1. Terlipressin is not approved by the FDA for use in the U.S. About Orphan Therapeutics, LLC Orphan Therapeutics, LLC, is a privately held drug development company dedicated to developing treatments for rare and serious diseases. It was founded in 2003 with the initial purpose to develop and seek U.S. FDA approval for its first product, LUCASSIN(R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) Type 1. About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company"s lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOmax is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Ikaria Holdings Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009